Price T Rowe Associates Inc Cure Vac N.V. Transaction History

Price T Rowe Associates Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.96 - $6.41 $3.42 Million - $5.53 Million	-863,425 Reduced 27.09%	2,324,274 $9.79 Million
Q3 2023 Nov 14, 2023	SELL	$6.5 - $10.77 $2.45 Million - $4.05 Million	-376,327 Reduced 10.56%	3,187,699 $21.8 Million
Q2 2023 Aug 14, 2023	SELL	$6.69 - $12.25 $1.67 Million - $3.06 Million	-249,870 Reduced 6.55%	3,564,026 $37.1 Million
Q1 2023 May 15, 2023	BUY	$6.38 - $12.5 $20.8 Million - $40.8 Million	3,260,031 Added 588.6%	3,813,896 $26.6 Million
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $3.18 Million - $4.71 Million	553,865 New	553,865 $3.34 Million
Q2 2022 Aug 15, 2022	SELL	$13.18 - $19.41 $5.94 Million - $8.75 Million	-450,642 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$14.73 - $35.25 $788,143 - $1.89 Million	-53,506 Reduced 10.61%	450,642 $8.84 Million
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $700,600 - $1 Million	20,777 Added 4.3%	504,148 $17.3 Million
Q3 2021 Nov 15, 2021	BUY	$49.26 - $74.5 $23.7 Million - $35.8 Million	480,297 Added 15624.5%	483,371 $26.4 Million
Q2 2021 Aug 16, 2021	SELL	$56.91 - $127.53 $77.8 Million - $174 Million	-1,367,014 Reduced 99.78%	3,074 $226,000
Q1 2021 May 17, 2021	BUY	$79.79 - $126.29 $8.16 Million - $12.9 Million	102,290 Added 8.07%	1,370,088 $125 Million
Q4 2020 Feb 16, 2021	BUY	$46.76 - $136.27 $59.3 Million - $173 Million	1,267,798 New	1,267,798 $103 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.